-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Novozymes reported organic sales growth of 4% in 2017, including 4% organic growth in the fourth quarter, 1% growth in Home Care, 9% in Food and Beverage, 11% in Bioenergy, and a decline in Agriculture and Feed3 %, technical-grade enzymes and the pharmaceutical industry grew 2%
.
The EBIT margin was 27.
9% (approximately 29% excluding one-time charges)
.
Free cash flow before the acquisition was DKK 2.
4 billion
.
.
The EBIT margin was 27.
9% (approximately 29% excluding one-time charges)
.
Free cash flow before the acquisition was DKK 2.
4 billion
.
Based on the good momentum of the business, as well as strong product innovation and opportunities, Novozymes expects 2018 sales to grow organically by 4% to 6%, with an EBIT margin of approximately 28%
.
.
Peder Holk Nielsen, president and chief executive officer of Novozymes, said, "2017 was satisfactory for solid growth and profitability
.
Similar to other years, 2017 saw different growth across different business groups, but due to Our supply of enzymes and microbial products to more than 40 industries provides ample dynamism for our business
.
In 2018 we will focus on increasing our investment in new and established customers, especially in emerging markets, while ensuring that we Able to innovate impactfully to meet the individual needs of customers
.
Although facing some uncertainties, based on good momentum, strong product innovation, and enhanced business activities, we are very optimistic about the achievement in 2018 and beyond.
Accelerated growth remains optimistic
.
"
.
Similar to other years, 2017 saw different growth across different business groups, but due to Our supply of enzymes and microbial products to more than 40 industries provides ample dynamism for our business
.
In 2018 we will focus on increasing our investment in new and established customers, especially in emerging markets, while ensuring that we Able to innovate impactfully to meet the individual needs of customers
.
Although facing some uncertainties, based on good momentum, strong product innovation, and enhanced business activities, we are very optimistic about the achievement in 2018 and beyond.
Accelerated growth remains optimistic
.
"
gist
Sales up 4% organically (4% in Q4); 3% in DKK (down 1% in Q3);
Growth in four of the five business segments
.
Food & Beverage, and Bioenergy performed very well;
.
Food & Beverage, and Bioenergy performed very well;
Novozymes' agriculture and feed business declined due to weak agricultural markets;
Four transformative innovations have been launched, and Novozymes aims to launch a total of 10 transformative innovations by 2020;
EBIT margin of 27.
9% (27.
9% in 2016); EBIT margin of 27.
6% in Q4 (28.
6% in Q4 2016);
9% (27.
9% in 2016); EBIT margin of 27.
6% in Q4 (28.
6% in Q4 2016);
Free cash flow before acquisitions of DKK 2.
4 billion, investment grew as expected;
4 billion, investment grew as expected;
Proposed dividend of DKK 4.
5 per share, an increase of 13%, with a payout ratio of 42%;
5 per share, an increase of 13%, with a payout ratio of 42%;
2018 full-year outlook: organic sales growth of 4% to 6% (with relatively stronger growth in the second half of the year), EBIT margin of approximately 28%, cash flow before acquisitions of DKK 2.
3 to 2.
6 billion, invested capital The rate of return is 24-25%
.
The share repurchase program is up to DKK 2 billion
.
The long-term dividend payout ratio has improved from about 40% of net profit to about 50%
.
3 to 2.
6 billion, invested capital The rate of return is 24-25%
.
The share repurchase program is up to DKK 2 billion
.
The long-term dividend payout ratio has improved from about 40% of net profit to about 50%
.
About Novozymes
Novozymes is a global leader in biological solutions
.
Novozymes works hand-in-hand with customers, partners and the global community to improve industrial efficiency while protecting the planet's resources and helping to build a better life
.
As the world's largest provider of enzymes and microbial technologies, Novozymes' bio-innovations can increase agricultural output, create renewable fuels, enable low-temperature washing, and bring benefits such as energy-efficient production, reduced waste emissions, and replacement of chemicals for the benefit of The present and future of mankind
.
Novozymes calls it "Rethink Tomorrow"
.
Novozymes shares are listed on Nasdaq OMX Copenhagen (symbol NZYM B )
.
For more details, please visit: www.
novozymes.
com or follow Novozymes' official WeChat account: Novozymes Biotechnology Expo
.
.
Novozymes works hand-in-hand with customers, partners and the global community to improve industrial efficiency while protecting the planet's resources and helping to build a better life
.
As the world's largest provider of enzymes and microbial technologies, Novozymes' bio-innovations can increase agricultural output, create renewable fuels, enable low-temperature washing, and bring benefits such as energy-efficient production, reduced waste emissions, and replacement of chemicals for the benefit of The present and future of mankind
.
Novozymes calls it "Rethink Tomorrow"
.
Novozymes shares are listed on Nasdaq OMX Copenhagen (symbol NZYM B )
.
For more details, please visit: www.
novozymes.
com or follow Novozymes' official WeChat account: Novozymes Biotechnology Expo
.
